IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway

[1]  D. Y. Hwang,et al.  IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation , 2018, Cell Death & Disease.

[2]  D. Yoon,et al.  Interleukin-32α Inhibits Endothelial Inflammation, Vascular Smooth Muscle Cell Activation, and Atherosclerosis by Upregulating Timp3 and Reck through suppressing microRNA-205 Biogenesis , 2017, Theranostics.

[3]  D. Yoon,et al.  Interleukin 32, inflammation and cancer , 2017, Pharmacology & therapeutics.

[4]  Zhiqing Liang,et al.  Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells , 2016, Oncotarget.

[5]  N. Sheikh,et al.  IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis , 2016, Mediators of inflammation.

[6]  D. Yoon,et al.  IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer , 2016, Oncotarget.

[7]  D. Matos,et al.  Genetic and Immunohistochemical Expression of Integrins ITGAV, ITGA6, and ITGA3 As Prognostic Factor for Colorectal Cancer: Models for Global and Disease-Free Survival , 2015, PloS one.

[8]  J. Snowden,et al.  The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours , 2015, British Journal of Cancer.

[9]  D. Cheresh,et al.  Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. , 2015, Trends in cell biology.

[10]  Z. Werb,et al.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.

[11]  S. Anand,et al.  Abstract 1916: β3 integrin/KRAS/RalB complex drives tumor stemness and resistance to EGFR inhibition , 2014 .

[12]  Yibang Chen,et al.  Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC , 2014, Apoptosis.

[13]  Jing Wang,et al.  An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition , 2014, Nature Cell Biology.

[14]  Cheng‐Yi Chen,et al.  Interleukin-32 Increases Human Gastric Cancer Cell Invasion Associated with Tumor Progression and Metastasis , 2014, Clinical Cancer Research.

[15]  D. Yoon,et al.  IL‐32γ enhances TNF‐α‐induced cell death in colon cancer , 2014, Molecular carcinogenesis.

[16]  R. Clarke,et al.  Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells , 2013, Breast Cancer Research.

[17]  Kai Li,et al.  Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. , 2013, Carcinogenesis.

[18]  D. Ahn,et al.  Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2. , 2012, Cancer letters.

[19]  D. Yoon,et al.  Interleukin‐32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3 , 2012, Immunology.

[20]  G. Camussi,et al.  Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. , 2011, Journal of the National Cancer Institute.

[21]  Fu-xiang Ran,et al.  β‐Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells , 2011, Molecular carcinogenesis.

[22]  M. Wicha,et al.  Breast cancer stem cells, cytokine networks, and the tumor microenvironment. , 2011, The Journal of clinical investigation.

[23]  D. Cheresh,et al.  αV integrins in angiogenesis and cancer. , 2011, Cold Spring Harbor perspectives in medicine.

[24]  H. J. Kim,et al.  IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals , 2011, Oncogene.

[25]  L. Joosten,et al.  Inflammation-dependent secretion and splicing of IL-32γ in rheumatoid arthritis , 2011, Proceedings of the National Academy of Sciences.

[26]  D. Tarin,et al.  Abstract 3841: An integrin αvβ3/c-Src oncogenic unit promotes anchorage independence and tumor progression , 2010 .

[27]  G. Mills,et al.  Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[28]  D. Tarin,et al.  Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression , 2009, Nature Medicine.

[29]  D. Yoon,et al.  Identification of the most active interleukin‐32 isoform , 2009, Immunology.

[30]  R. Baron,et al.  Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases , 2007 .

[31]  S. Akira,et al.  Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis , 2005, The Journal of experimental medicine.

[32]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[33]  P. Foubert,et al.  Integrins in Tumor Angiogenesis & Lymphangiogenesis , 2017 .

[34]  K. O'Byrne,et al.  IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. , 2013, Lung cancer.

[35]  P. Foubert,et al.  Integrins in tumor angiogenesis and lymphangiogenesis. , 2012, Methods in molecular biology.

[36]  R. Baron,et al.  Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. , 2007, Cancer research.

[37]  D. Yoon,et al.  Interleukin-32: a cytokine and inducer of TNFalpha. , 2005, Immunity.